Chemical Biology Core FacilityPublications
The E6 oncoprotein of human papillomavirus 16 as a therapeutic target
Dymalla, S; Butz, K; Lohrey, C; Scheffner, M; Sehr, P; Lewis, J; Hoppe-Seyler, F
Molecular Cancer Therapeutics Dec 20007 6(12)
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
Hose, D., Reme, T., Meissner, T., Moreaux, J., Seckinger, A., Lewis, J.D., Benes, V., Benner, A., Hundemer, M., Hielscher, T., Shaughnessy JD, J.r, Barlogie, B., Neben, K., Kramer, A., Hillengass, J., Bertsch, U., Jauch, A., De Vos, J., Rossi, J.F., Mohler, T., Blake, J., Zimmermann, J., Klein, B. & Goldschmidt, H.
Blood. 2009 Apr 30;113(18):4331-40. Epub 2009 Jan 26. PubMed
Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein.
Bartonova, V., Igonet, S., Sticht, J., Glass, B., Habermann, A., Vaney, M.C., Sehr, P., Lewis, J.D., Rey, F.A. & Krausslich, H.G.
J Biol Chem. 2008 Nov 14;283(46):32024-33. Epub 2008 Sep 4. PubMed
The structural basis for cap binding by influenza virus polymerase subunit PB2.
Guilligay, D., Tarendeau, F., Resa-Infante, P., Coloma, R., Crepin, T., Sehr, P., Lewis, J.D., Ruigrok, R.W., Ortin, J., Hart, D.J. & Cusack, S.
Nat Struct Mol Biol. 2008 May;15(5):500-6. Epub 2008 May 4. PubMed
Thanatop: a novel 5-nitrofuran that is a highly active, cell-permeable inhibitor of topoisomerase II.
Polycarpou-Schwarz, M., Muller, K., Denger, S., Riddell, A., Lewis, J.D., Gannon, F. & Reid, G.
Cancer Res. 2007 May 1;67(9):4451-8. PubMed
Evaluation of Different Glutathione S-Transferase-Tagged Protein Captures for Screening E6/E6AP Interaction Inhibitors Using AlphaScreen(R).
Sehr P, Pawlita M, Lewis, J.D.
J Biomol Screen 2007/05
The role of the chemical biology core facility at EMBL: a vision for a European roadmap.
Lewis, J.D.
ACS Chem Biol. 2007 Jan 23;2(1):21-3. PubMed
Systematic discovery of new recognition peptides mediating protein interaction networks.
Neduva, V., Linding, R., Su-Angrand, I., Stark, A., de Masi, F., Gibson, T.J., Lewis, J.D., Serrano, L. & Russell, R.B.
PLoS Biol. 2005 Dec;3(12):e405. Epub 2005 Nov 15. PubMed
The role of RNA interference in drug target validation: Application to Hepatitis C.
Ostareck-Lederer, A., Clauder-Münster, S., Thermann, R., Polycarpou-Schwartz, M., Gentzel, M., Wilm, M. & Lewis, J.D.
In "RNA Interference Technology", Appasani, K. (ed.), 2005, Cambridge University Press, pp. 318-330
Structure of the hepatitis C virus IRES bound to the human 80S ribosome: Remodelling of the HCV IHRES.
Boehringer, D., Thermann, R., Ostareck-Lederer, A., Lewis, J.D. & Stark, H.
Structure 2005 13(11) 1695-1706